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1. Introduction
Francisella tularensis is a Gram-negative facultative intracellular bacterium that can infect a
variety of species and is the cause of the disease known as tularemia or rabbit fever (Sjostedt,
2007). Infection can result by exposure to the bacterium by contact with the skin, by ingestion,
or by inhalation of aerosolized organisms (Ellis et al., 2002; Sjostedt, 2007). The precise course
and kinetics of the disease varies with the Francisella strain and route of inoculation (Chen et
al., 2003; Conlan et al., 2003). However, all routes of exposure can ultimately result in sepsis
and widespread dissemination of the bacteria in the host (Conlan et al., 2003; Elkins et al.,
2003). Inoculation with microorganisms in aerosolized form for some strains of F. tularensis
has a remarkably low infectious dose (10 organisms or less) with a significant fatality rate if
left untreated (Conlan et al., 2003; Twine et al., 2006). Tularemia can be treated with antibiotics
if detected early (Hepburn and Simpson, 2008; Kman and Nelson, 2008). However, the
possibility that the organism could be made antibiotic resistant, either through classic
microbiologic means or by using recombinant DNA technology, is a considerable concern if
the modified organism were then intentionally spread. The extreme virulence of certain strains,
the ability to aerosolize the organisms and the ability of the organism to persist in the
environment make it a potent potential bioweapon (Altman, 2002; Ellis et al., 2002). Indeed,
both the former Soviet Union, as well as the United States, reportedly had a bioweapons
program employing F. tularensis (Dennis et al., 2001; Fong and Alibek, 2005). Unfortunately,
in comparison to other pathogenic microorganisms, the host response to F. tularensis is not
yet well understood.
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The immune response to Francisella tularensis appears complex. As might be anticipated for
an intracellular organism, classical cellular immune responses appear to be critical. Studies
using lymphocyte-deficient (CD4−, β2m−, TCR-γ−, TCR-β−, scid, nude) or lymphocyte-
depleted (by using specific antibodies) mice have illustrated an important role for both CD4
and CD8 T cells (Conlan et al., 1994; Elkins et al., 1993; Elkins et al., 1996; Rhinehart-Jones
et al., 1994; Yee et al., 1996). Interestingly, there is also an unusual Thy1+ αβ TCR+ CD4−
CD8− NK1.1− T cell subset that has been shown to contribute to protection against F.
tularensis challenge (Cowley and Elkins, 2003; Cowley et al., 2005). Recent studies have also
suggested that IgA antibodies as well as CD4+ T cells may also play a role in the context of
intranasal immunization with an inactivated strain of F. tularensis, in conjunction with IL-12
as an adjuvant (Baron et al., 2007). Thus, while the immune response against F. tularensis is
clearly multifactorial, it seems that a cellular response, including CD4+ and CD8+ T cells, plays
a critical role in protection.
There is no FDA approved vaccine for F. tularensis. During the 1940s an attenuated subsp.
holarctica Live Vaccine Strain (LVS) was developed (Eigelsbach and Downs, 1961) as a
vaccine candidate. This strain has proven invaluable for examining aspects of the F.
tularensis-host interaction (Elkins et al., 2007). While LVS has greatly aided our understanding
of F. tularensis biology and microbial host interactions, there are significant side effects to the
use of LVS as a vaccine and the protection it affords is incomplete (Griffin et al., 2007; Saslaw
et al., 1961a; Saslaw et al., 1961b). The drawbacks of the current LVS vaccine, and the
possibility that F. tularensis might be used in a bioterror weapon, have added impetus to the
identification of antigens recognized by the immune system. Currently, the nature of the
protective antigens, indeed the molecular definition of any antigens in the cellular immune
response, is limited. There have been only a few reports of immunostimulatory molecules for
T cells in mice or humans (Golovliov et al., 1995; Lee et al., 2006; McMurry et al., 2007;
Sjostedt et al., 1992; Sjostedt et al., 1991). Perhaps the best-characterized response is to the
lipoprotein Tul4. Tul4 can be a target of the cellular and humoral immune response in both
mice and humans (Golovliov et al., 1995; Sjostedt et al., 1992; Sjostedt et al., 1991). Mice are
a natural host for F. tularensis infection and exhibit many of the same aspects of the infection
in humans (Fortier et al., 1991). Interestingly, mice immunized with Salmonella
typhimurium expressing Tul4 appeared to give partial protection as assessed by a decreased
bacterial burden in spleen and liver (Sjostedt et al., 1992). It would be extremely valuable to
define epitopes at the molecular level in mice so that the immune response could be
quantitatively and qualitatively assessed. This would be a great aid in understanding the host
immune response in the context of infection as well as helping to develop and assess vaccine
vectors and immunization strategies. In the current study, we have defined in Tul4 a potential
immunodominant epitope in B6 mice using a novel strategy and shown that it is an important
epitope in the context of a F. tularensis infection in both the acute and memory immune
response.
2. Materials and Methods
2.1. Mice, cell lines, and bacteria
C57BL/6J (H2b) (B6) mice were purchased from the Jackson Laboratory (Bar Harbor, Maine).
MHC class II knockout mouse B6.129-H2Abtm1Gru was generously provided by Dr. Andrea
Sant (University of Rochester). The T cell fusion partner BWZ.36/CD8+, which can be used
to make MHC class II and class I restricted hybridomas, was kindly provided by Dr. Nilabh
Shastri and maintained as previously described (Sanderson and Shastri, 1994). The F.
tularensis live vaccine strain (LVS) was used in these studies (Cowley and Elkins, 2003).
Bacterial viability was quantified by serial dilution on chocolate agar.
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2.2. Fusion protein constructs and peptides
Recombinant proteins were generated using the bacterial expression vector pQE40, which
contains a 6x histidine coding region (6x His) followed by murine dihydrofolate reductase
(DHFR). The DHFR-Tul4 construct was constructed by cloning full length Tul4 from F.
tularensis Live Vaccine Strain (LVS) genomic DNA using polymerase chain reaction (PCR)
and the specific primers described below. All primers were constructed with 15–18 base pairs
complimentary to the sequence of interest and included an enzyme restriction site and a GC
clamp. The 3′ reverse primers also included a stop codon upstream of the restriction site. The
Tul4 insert was cloned into the pQE40 vector using BglII and PstI restriction sites designed
into the primers. DHFR-OVA encoded in the pQE40 vector was created in a similar fashion.
Tul4 fusion protein deletion constructs were created by using the same 5′ primer and
substituting with nine individual 3′ primers that recognize sequences starting at 384 base pairs
(bp), 369 bp, 345 bp, 324 bp, 300 bp, 282 bp, 183 bp, and 89 bp. The Tul4 transplant epitope
construct (DHFR-Tul4 86-110) was created by cloning out a 25 amino acid (aa) region from
Tul4 using a specific primer set. This region was cloned into pQE40 using BglII and PstI sites
engineered into the primers yielding a ‘transplanted’ region of Tul4 fused directly behind
DHFR. Tul4 transplant epitope deletion constructs were created by using a constant 5′ primer
recognizing a region found before the DHFR sequence and substituting individual 3′ primers
producing the segments of Tul4 86-99 (14 aa), 86-98 (13 aa), 86-97 (12 aa), and 86-95 (10 aa)
fused to DHFR. Site directed mutagenesis of a cysteine to serine at residue 97 by an additional
3′ primer produced the DHFR-Tul4 86-(C97S)-99 construct. All synthetic Tul4 peptides used
in this paper Tul4 86-99 (RLQWQAPEGSKCHD), Tul4 86-(C97S)-99
(RLQWQAPEGSKSHD), Tul4 86-98 (RLQWQAPEGSKCH), Tul4 86-97
(RLQWQAPEGSKC), and Tul4 86-95 (RLQWQAPEGS) were synthesized by SynBioSci
(Livermore, CA). The NP 118-126 peptide derived from LCMV (RPQASGVYM) and OVA
323-339 peptide (ISQAVHAAHAEINEAGR) served as irrelevant peptide negative controls
and were synthesized by Macro-Molecular Resources (University of Colorado, Ft. Collins,
CO).
2.3. Protein Production
Production of DHFR-OVA and all DHFR-Tul4 fusion proteins were performed in Escherichia
coli strain M15 as described by manufacturers specifications (Qiagen, Valencia, CA).
Recombinant proteins were isolated by lysing the bacterial pellets with 8M urea (pH7.5) and
purified over Ni-NTA column (Qiagen). The DHFR-Tul4 was dialyzed with PBS to remove
urea before injection. To couple tosylactivated M280 magnetic Dynabeads (Invitrogen,
Carlsbad, CA), 1×107 beads with 8μg protein were mixed overnight at 37°C in 0.1M borate
buffer, washed three times with PBS using magnetic separation, and diluted to working volume
in PBS (2×105 beads/μl). Tul4 deletion construct production and characterization was
confirmed by SDS-PAGE techniques and Coomassie Blue staining as described previously
(Turner et al., 2001).
2.4. Generation of T cell hybridomas
T cell hybrids were produced in two ways. To ensure that the epitopes recognized by the hybrids
were generated in a natural infection, mice were inoculated intradermally at the base of the tail
with 1 × 105 viable F. tularensis LVS and allowed to clear the infection. At least 3 weeks later,
mice were sacrificed and spleen cells restimulated in vitro using F. tularensis LVS infected
spleen cells. Restimulation was performed for 5 days and the cells harvested (FACS analysis
confirmed cells were predominantly T cells) and fused with BWZ.36/CD8+ cells. Colonies
were selected in HAT and tested for activity using either infected spleen cells as APC, or spleen
cells and soluble F. tularensis LVS extracts as previously described (Woolard et al., 2008).
Activity was measured using the CPRG substrate in 96 well plates as previously described
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(Sanderson and Shastri, 1994). Positive wells were cloned by limiting dilution and retested.
For the hybridomas generated with recombinant protein immunization, mice were injected in
the footpad with approximately 12.5μg DHFR-Tul4 protein emulsified in complete Freund’s
adjuvant and were boosted once with DHFR-Tul4 protein emulsified in incomplete Freund’s
adjuvant before harvesting draining popliteal lymph node. Lymph node cells from the
immunized mice were stimulated in vitro and after 3 rounds of in vitro restimulation with
DHFR-Tul4 conjugated to tosylactivated M280 beads, lymphocytes were isolated by
Lympholyte-M (Cedarlane Laboratories Lmtd, Ontario, Canada) and fused to the BWZ.36/
CD8+ fusion partner containing lacZ driven by the Interleukin-2 promotor element as described
(Sanderson and Shastri, 1994; Turner et al., 2001). Activity was measured using the beta-
galactosidase substrate in 96 well plates as previously described (Turner et al., 2001).
2.5. Antigen presentation assay
Antigen presentation assay was adapted from the T cell antigen discovery (T-CAD) assay
described by Turner et al. (Turner et al., 2001). Presentation assays were performed by
incubating Tul4 specific hybridomas: 2×105 ID6 hybrids with 1×105 APCs or 4×105 FT13
1E4B4 hybrids with 4×105 APCs in 200μl total volume per well in a 96 well tissue culture
plate. APCs were splenocytes isolated from naïve wild type or MHC class II knockout C57BL/
6J mice as described in the figure legends. Recombinant proteins DHFR-OVA, DHFR-Tul4,
or the individual Tul4 deletion constructs isolated from bacterial lysates were conjugated to
tosylactivated beads as described above and used at 2×106 beads per well. Assays were also
performed in the presence of synthesized peptides Tul4 86-99, Tul4 86-(C97S)-99, Tul4 86-98,
Tul4 86-97, Tul4 86-95 at 10μg (SynBioSci, Livermore, CA), 2μg NP peptide, and 3.8μg F.
tularensis extract. F. tularensis extract was produced by killing F. tularensis LVS in 70%
ethanol (Woolard et al., 2007). Plate bound anti-CD3 (clone 500A2) (BD Pharmingen, San
Jose, CA) was also included in each assay (not shown in figures) as a positive control for hybrid
viability and ability to function. After 18–24 hour incubation at 37°C, cultures were developed
using the beta-galactosidase assay. Briefly, the beta-galactosidase assay utilizes hybridomas
containing the β-galactosidase gene (lacZ) under the control of the Interleukin-2 promotor
elements (NFAT elements). Because these hybridoma have the reporter gene beta-
galactosidase under the control of IL-2 promoter elements, and IL-2 indiction is an early event
in T cell activation, activation of the hybridoma is accompanied by production of the enzyme
beta-galactosidase that can be easily monitored using a colorimetric substrate (Sanderson and
Shastri, 1994; Turner et al., 2001). When the β-galactosidase substrate X-gal (5-bromo-4-
chloro-3-indolyl-β-D galactosidase) (Invitrogen, Carlsbad, CA) is administered a colorimetric
substrate is produced turning activated hybridomas blue and the number of activated hybrids
per well can then be enumerated by visual counts. Wells with low numbers of activated (<
1000 blue cells) the entire well was counted. Wells with high numbers (>1000 blue cells) three
representative fields of view were counted, averaged, and multiplied by the number of fields
per well. In some experiments, levels of beta-galactosidase expression was assayed using the
soluble substrate chorophenol red-β D-galactopyranoside sodium salt (CPRG), allowing for
identification of the overall reactivity of a hybridoma. This assay results in a colorimetric
substrate from activated hybridomas and the absorbance can be measured using a
spectrophotometer at OD570nm (Sanderson and Shastri, 1994).
2.6. Analysis of in vivo immunogenicity
Analysis of in vivo immunogenicity was performed essentially as previously described
(Woolard et al., 2008). In brief, B6 mice were inoculated with 105 CFU F. tularensis LVS
intradermally at the base of the tail. Spleens were harvested on day 7 to examine the acute
response or, to characterize the memory response, mice were allowed to clear the infection and
spleens were harvested approximately 2 months post inoculation. Splenocytes from both
infected mice and uninfected controls were stimulated in vitro for 18–24 hours with 100μg/ml
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F. tularensis LVS extract, Tul4 86-99 peptide, or an irrelevant class II OVA 323-339 peptide.
Brefeldin A was added for the last four hours of incubation. Cells were then washed and surface
stained with anti-CD19 (B-D Pharmingen), PE-Cy7 (Caltag), anti-CD11c PE-Texas Red
(Invitrogen), anti-CD11b APC750 (eBiosciences), anti-TCRβ Alexa 488 (Biolegend), anti-
CD3 APC (eBiosciences), anti-CD4 PacBlue (Invitrogen), anti-CD8 PerCP (Biolegend) and
anti-IFN-γ (B-D Biosciences) fixed and permeablized using eBioscience reagents and
protocols (eBioscience, San Diego, CA), then stained with PE conjugated antibody to IFNγ
and analyzed on a Cyan flow cytometer (Dako-Cytomation, Colrado Springs). The gating
scheme used has been included in Fig. 6A. TCRβ+CD3+CD4+ splenocytes were analyzed for
intracellular IFNγ with a minimum of 250,000 total cellular events accumulated. All FACS
results were analyzed using Summit software (Dako-Cytomation).
3. Results
3.1. Generation and characterization of Tul4 reactive hybridomas
In the current study, we have used two different approaches to immunization in conjunction
with the T-CAD technique to identify an epitope that arises against the F. tularensis lipoprotein
Tul4. To identify epitopes present in both natural infection and conventional immunization
with recombinant fusion protein, hybridomas were created by fusing lymphocytes derived from
these two immunization methods to a variant of the BWZ.36 (lacZ+) T cell fusion partner.
Hybridomas generated from these fusions that were activated by plate bound anti-CD3, reactive
with DHFR-Tul4 coupled to tosylactivated beads and F. tularensis extract, and did not react
with DHFR-OVA coupled to tosylactivated beads or irrelevant NP peptide were deemed as
having the appropriate reactivity pattern. Based upon a combination of absolute strength of
reactivity, the signal to noise ratio, and relative stability, two hybridomas were selected for
detailed analysis, one from immunization with recombinant Tul4 fusion protein (ID6) and one
from infection with live F. tularensis LVS (FT13 1E4B4). These hybridomas were activated
by anti-CD3, F. tularensis extract, and DHFR-Tul4 indicating that these hybridomas are
specific for Tul4 and the absence of reactivity with DHFR-OVA suggests that the hybridomas
do not recognize the DHFR portion of the fusion protein (data not shown). Interestingly, the
FT13 1E4B4 hybridoma generated from live F. tularensis infection was not only activated by
F. tularensis extract but also DHFR-Tul4 which was recombinantly expressed in E. coli and
was coupled to beads. These data suggest that we have generated and identified hybridomas
from live F. tularensis infection and recombinant protein immunization that specifically
recognize a recombinant DHFR-Tul4 in an in vitro antigen presentation assay.
3.2. Generation of Tul4 deletion constructs and identification of an epitope region within Tul4
A series of DHFR-Tul4 deletion constructs were created in the pQE40 bacterial expression
vector to identify the epitope containing regions within Tul4 recognized by the hybridomas.
These constructs contain the 6x His tag followed by DHFR and the C terminal deletions of
Tul4 illustrated in Fig. 1A. E. coli bacterial lysates induced to express the deletion constructs
were then purified over a Ni-NTA column to isolate fusion proteins via the 6x His tag and
purified fusion proteins were then analyzed for appropriate molecular weight as well as quality
and quantity of protein using SDS-PAGE (Fig. 1B). The predicted molecular weight of DHFR-
Tul4 is 45kDa (28kDa DHFR plus 17kDa Tul4) (Fig. 1Ba) with the C terminal deletion
constructs having correspondingly lower molecular weights (Fig. 1B b-i). Note that the
presence of a 28kDa band in lanes a-i is likely due to DHFR protein, which may have arisen
from proteolytic cleavage at the junction of DHFR-Tul4 peptides. These results show that the
constructs encode fusion proteins with the appropriate molecular size, which can be
successfully expressed and subsequently used for mapping studies.
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Using the hybridomas and Tul4 deletion constructs, antigen presentation experiments were
conducted to identify the T cell epitopes within Tul4. Deletion constructs were individually
coupled to tosylactivated beads which serves two purposes in our assay: allowing for
purification of recombinant protein from a urea buffer used in the protein isolation process; as
well as increasing antigen uptake and processing and presentation by APCs to the hybridomas
(Storozynsky et al., 1999). Presentation assays were done as described previously in the
methods section and activated hybridomas were identified by beta-galactosidase assay and
quantified by visually counting blue cells (activated cells). As seen in Fig. 2, both hybridomas
are activated when the first 100 amino acids of Tul4 are present but lose reactivity when 94
amino acids of Tul4 were presented by APCs. A loss of reactivity identified by a reduction in
the number of activated (blue) cells suggests that the epitope recognized by these hybridomas
is no longer present within the DHFR-Tul4 fusion protein. Interestingly, both hybridomas, one
from conventional immunization and one from live bacterial infection, lose reactivity at the
same location on the Tul4 protein suggesting that the two immunization approaches generate
hybridomas that recognize the same epitope.
3.3. Fine epitope mapping using expression constructs
The previous experiments using the Tul4 deletion constructs indicated that the hybridomas
recognize an epitope that is lost when only 94 residues of Tul4 are present. We reasoned that
an epitope could lie ~10 amino acids upstream or downstream of the 94th residue. To
unequivocally identify that an epitope exists within this region of Tul4, a fusion protein was
generated from full length Tul4 by PCR using primers specific to the region mentioned. This
resulted in transplantation of amino acids 86-110 of Tul4 directly behind DHFR (Fig. 3A).
This construct, called Tul4 transplant epitope protein, DHFR-Tul4 86-110, containing only 25
amino acids of Tul4 was capable of activating both hybridomas, illustrating that an epitope
does indeed exist within this 25 amino acid sequence (Fig. 3B&C). Additionally, splenocytes
from MHC class II deficient mice were not capable of activating either hybridoma indicating
that the epitope recognized is class II restricted (Fig. 3C).
To further refine the minimal epitopes recognized by each hybridoma, deletion constructs of
the DHFR-Tul4 86-110 epitope transplant were created. Additional residues were removed
from DHFR-Tul4 86-110 as described in the Methods section to generate the Tul4 transplant
epitope deletion proteins DHFR-Tul4 86-99, 86-98, 86-97, and 86-95 which were individually
coupled to tosylactivated beads for use in reactivity assays (Fig. 3A&B). Hybridoma reactivity
against DHFR-Tul4 86-99 is similar to that elicited by the DHFR-Tul4 86-110 even though
the protein containing residues 86-99 is 10 amino acids shorter. In both hybridomas a noticeable
loss of reactivity is seen with DHFR-Tul4 86-98 and 86-97 proteins. These data indicate that
a similar minimal epitope for each of the hybridomas is found within amino acids 86-99 with
significant residues at 97 and 98. Because the peptide contained a cysteine, which might be
modified either in vitro or in vivo we also changed the cysteine at residue 97 by site directed
mutagenesis to a serine, generating DHFR-Tul4 86-(C97S)-99 (Thompson et al., 2004). As
seen in Fig. 3B the DHFR-Tul4 86-(C97S)-99 protein had similar stimulatory potential when
compared to its wildtype counterpart in these hybrids. Together, these data indicate that an
epitope of Tul4 is located within residues 86-99.
3.4. Fine epitope mapping using peptides
Synthetic peptides were used to determine the epitope of Tul4 recognized by the hybridomas.
A synthetic peptide of residues 86-99 was tested and was found to be capable of activating
both hybridomas showing definitively that an epitope of Tul4 is found at residues 86-99 (Fig.
4). We then sought to refine our epitope region using truncated peptides of Tul4. As seen in
Fig. 4 both hybridomas are activated by peptides Tul4 86-98 and Tul4 86-97 and lose reactivity
with Tul4 86-95, suggesting that the hybridomas recognize a similar minimal epitope found
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between residues 86 to 97. Overall, the peptide mapping experiment results nevertheless are
very similar to those seen with the protein expression constructs. The peptide data does appear
to differ slightly from DHFR fusion protein data regarding the reactivity of Tul4 86-98 and
Tul4 98-97, which might reflect differences in processing of the fusion protein not required
with the peptides. As described above, the sequence of peptide comprised by Tul4 86-99
contains a cysteine at residue 97. As before, to investigate whether or not the cysteine affects
reactivity, Tul4 86-99 with a point mutation at Cys97 to Ser97 was also synthesized. The altered
residue did not decrease and may slightly increase the stimulatory capability of the Tul4 86-
(C97S)-99 peptide (Fig. 4). These data corroborate the fusion protein data (Fig. 3). Using
synthetic peptides we have obtained similar findings to those from the fusion protein screen
and have conclusively identified an epitope within residues 86 to 99 and as minimal as residues
86 to 97 of Tul4 that arise in both natural infection and classical protein immunization.
We also tested six hybridomas that were shown to react with Tul4 from F. tularensis LVS to
determine if they react with Tul4 in extracts from the virulent F. tularensis Schu S4 strain. As
can be seen in Figure 5, all of the hybridomas reacted with the Schu S4 extract indicating not
only that the epitope is shared and processed similarly, but also that it is produced in sufficient
amounts to stimulate these cells. While the cross-reactivity of the F. tularensis strains is
illustrated by recognition of both SchuS4 and LVS extracts by all of the hybridomas, their
levels of reactivity are variable, which may reflect different fine specificity amongst the
hybridomas.
3.5. In vivo validation of Tul4 as a natural epitope
To determine if Tul4 was recognized during acute infections and was incorporated into the
memory pool, we examined the F. tularensis specific IFN-γ responses of mice either 7 days
(acute infection) or 2 months (memory response) after intradermal inoculation with 105 F.
tularensis LVS. Splenocytes from control and infected mice were isolated and stimulated in
vitro for 18–24 hours with F. tularensis extracts, Tul4 86-99 peptide, and irrelevant OVA
protein or media alone as negative controls. Cells were then stained using an array of cellular
markers followed by analysis via multicolor flow cytometry, which allowed for identification
of activated IFNγ positive CD4+ T cells and exclusion of B cell, dendritic cell, and monocyte
populations (Fig. 6A). When CD4+ splenocytes from mice with acute infection (7 days post-
infection) were analyzed, we saw that a large proportion were reactive with F. tularensis extract
(FT Ag) (6.6×105 IFNγ+ CD4+ per spleen) and a significant portion was also reactive with
Tul4 86-99 peptide (2.5×105 IFNγ+ CD4+ per spleen) with minimal background IFNγ secretion
by cells activated by OVA (Fig. 6B). These data suggest that the Tul4 86-99 epitope occurs
naturally during acute infection and is one of the major epitopes in an anti-F. tularensis
response.
It was also of interest to examine whether or not Tul4 reactive T cells are found in the memory
T cell compartment. To examine the memory response, mice were infected as previously
described and were allowed to clear infection, approximately 2 months later splenocytes were
isolated, activated, and subsequently analyzed by flow cytometry (Fig. 6C). A significant
proportion of CD4+ cells within the memory response could be activated by F. tularensis
extracts (3.6×104 IFNγ+ CD4+ per spleen) and Tul4 86-99 peptide (2.5×104 IFNγ+ CD4+ per
spleen) above that of background IFNγ levels (1.0×104 IFNγ+ CD4+ per spleen) (Fig. 6C).
These data further suggest that the Tul4 86-99 epitope generates CD4 T cells that arise in acute
infection, persist through the contraction phase of an immune response, and survive into the
memory repertoire.
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The current report describes a dominant class II restricted T cell epitope of a Francisella antigen
in the C57BL/6 mouse model of infection. The epitope of Tul4 encoded by amino acids 86-99
is to our knowledge, the first validated murine epitope described for Tul4. While there are a
number of strategies for identifying T cell epitopes (Doolan et al., 2003; Sette and Peters,
2007), here we have used the T-CAD assay (Turner et al., 2001), a cell-based functional assay
which makes no a priori assumptions regarding the biochemical properties of the epitope, to
define an epitope of Francisella. Interestingly, previous mouse studies using a recombinant
Salmonella typhimurium vector expressing Tul4, implicated the Tul4 protein as an important
antigen in the response against F. tularensis (Sjostedt et al., 1992) and our work complements
and extends these studies. In that study, three B cell epitopes were described, and a proliferative
response of splenocytes to Tul4 was also shown, however, T cell epitopes were not defined
(Sjostedt et al., 1992). Studies from tularemic humans revealed that the Tul4 protein was
capable of stimulating a proliferative and cytokine response from PBMCs and three T cell
stimulating polypeptides of approximately 20-24 amino acids of Tul4 were identified (Sjostedt
et al., 1990). Together these data implicate Tul4 as a significant antigen in both the murine and
human responses against Francisella and suggests that Tul4 might serve as a relevant model
antigen to investigate host immune responses against Francisella.
One of the most surprising findings of the current study was that the analyses of T cell responses
generated from live bacterial infection and conventional immunization using purified protein
revealed the same epitope. One might have predicted that antigens from these immunizations
might be processed and presented very differently. During Francisella infection, the bacteria
reside within APC such as macrophages and dendritic cells (Oyston et al., 2004), and thus the
antigen would be from an endogenous source, whereas in the conventional immunization, the
source of antigen is exogenous. Interestingly, recent data has highlighted a pathway termed
autophagy, in which endogenous antigen can be effectively processed and presented in the
context of class II MHC molecules (Crotzer and Blum, 2005; Strawbridge and Blum, 2007).
Autophagic pathways have been hypothesized to play an important role in the response to
pathogens (Crotzer and Blum, 2005; Deretic, 2006). Relevant in this regard, Francisella can
be found in autophagic vesicles, providing evidence for a mechanism by which Francisella
antigens could be shuttled between processing compartments (Checroun et al., 2006) and a
recent study has shown these autophagic vesicles to be MHC-II positive (Hrstka et al., 2007).
However, other sources of antigen might also be available due to the release of dead and dying
bacteria, which might occur during the natural course of infection which then could be
presented in the traditional class II antigen presentation pathway (Sant et al., 2007; Vyas et al.,
2008). Whatever pathways are operational, it will be important to determine if other antigens
behave the same as Tul4 and whether the epitopes are the same in the context of an infection
and in a conventional protein immunization. If so, since prior immunization can dramatically
affect the immunodominance hierarchy of a T cell response (Cole et al., 1997; Sant et al.,
2007; Yewdell and Bennink, 1999) immunization with individual proteins may allow one to
focus the immune response to epitopes which can be recognized in the context of a natural
infection, but which are normally subdominant or weakly recognized. Examples of attractive
targets for this strategy include proteins essential for intracellular growth or virulence, such as
the proteins encoded by the pathogenicity island genes (Nano and Schmerk, 2007).
The results from the in vivo experiments have validated the Tul4 86-99 epitope and show that
it is recognized by T cells in an infection model. Interestingly, we found multiple hybridomas
that recognized the Tul4 86-99 peptide, which is consistent with it being a significant epitope
in the response to F. tularensis. However, because the T cells were re-stimulated in culture
prior to fusion, and only a few fusions were analyzed, hybridoma reactivity cannot be used to
rigorously establish the frequency of responding T cells and dominance in the immune
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response. However, analyses of T cells from infected animals directly illustrates that Tul4
86-99 is a major epitope recognized. For example, in the acute response, a significant
proportion of CD4+ splenocytes were activated by Tul4 86-99 peptide. In one mouse, as much
as 20% of total acute response to F. tularensis extract can be attributed to T cells that recognize
Tul4 86-99. Moreover, a significant proportion of T cells recognize Tul4 86-99 epitope two
months after infection, suggesting that Tul4 reactive T cells enter the long-term memory pool,
a critical property of a potential vaccine candidate. Both the ID6 and FT13 1E4B4 hybridomas
were capable of being activated by both LVS and SchuS4 extracts revealing that there is
significant cross-recognition of the Tul4 86-99 epitope, as one might predict given the
homology of Tul4 between the strains (Titball and Petrosino, 2007). Importantly, these
experiments also show Tul4 is expressed at sufficient levels by both strains, since closely
related, or even identical, proteins can be regulated very differently between different bacterial
strains, even altering their virulence (Beyhan et al., 2006).
Immunization with Tul4, either using recombinant S. typhimurium expressing Tul4 or Tul4
formulated with immunostimulating complexes (ISCOMs), can provide partial protection in
mice (Golovliov et al., 1995). Intriguingly, Tul4 has recently been shown to function in the
innate response to F. tularensis via signaling through TLR2 (Thakran et al., 2008), whether
this is related to its ability to function in protection is as yet unknown. While reports suggest
that Tul4 may be relevant in a protective response (Thakran et al., 2008), it is likely that a
polyvalent vaccine will be required to be a fully efficacious and a number of approaches with
this goal are underway (Baron et al., 2007; Duckett et al., 2005; Eyles et al., 2008; Golovliov
et al., 1995; Isherwood et al., 2005; Sjostedt et al., 1992). The identification of the defined Tul4
86-99 epitope, and the recent identification of epitopes of Francisella in humans (McMurry et
al., 2007) will allow the quantitative assessment of T cell responses using ELI-spot techniques,
intracellular cytokine staining, or analyses using MHC tetramers, and thus will be invaluable
in examining the immune response to Francisella in the context of infection or in vaccine
studies.
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Figure 1. Generation of DHFR-Tul4 deletion constructs for epitope identification
(A) Schematic of full length Tul4 and the eight carboxy-terminal deletion constructs used in
the pQE40 bacterial expression vector. The black box indicates 6 × histidine tag, the gray box
indicates murine DHFR protein, and open box denotes portions of Tul4 protein fused in frame
with DHFR. (B) SDS-PAGE analysis of Tul4 and deletion constructs. Constructs were purified
over Ni-NTA column, separated on SDS-PAGE gel, and stained with Coomassie Blue. Gel
lane headings (a-i) correspond to constructs (a-i) in panel (A). The molecular mass of full length
Tul4 fused with DHFR is approximately 45kDa.
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Figure 2. Hybridoma reactivity against DHFR-Tul4 deletion proteins
Hybridomas were incubated with C57BL/6 splenocytes and F. tularensis extract, NP peptide,
and tosylactivated beads adsorbed with the various DHFR-Tul4 deletion proteins or DHFR-
OVA. After overnight incubation, a beta-galactosidase assay was done to identify activated
cells. Representative data for reactivity patterns are shown (All treatments done 3 times or
more).
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Figure 3. Hybridomas recognize a similar minimal epitope in a DHFR-Tul4 fusion protein
(A) Schematic of the approximate location of transplant epitope in the context of full length
Tul4 and the Tul4 transplant epitope construct (25 amino acids of Tul4) along with its deletion
constructs (14, 13, 12, and 10 amino acids of Tul4). (B) Hybridomas were incubated with
C57BL/6 splenocytes, DHFR-Tul4 proteins, and controls. Tosylactivated beads were
conjugated with DHFR-OVA, DHFR-Tul4, or the individual Tul4 transplant epitope proteins
(DHFR-Tul4 86-110, -99, -(C97S)-99, -98, -97, -95). After overnight incubation, a beta-
galactosidase assay was performed to identify activated cells. Representative data for reactivity
patterns are shown (All treatments done 3 times or more). (C) Hybridomas were incubated
with wild type (filled bars) or MHC class II knockout (open bars) splenocytes, FT extract,
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DHFR-Tul4, DHFR-OVA, and DHFR-Tul4 86-110 as done previously. (Similar results were
obtained with 3 additional independent Tul4 reactive hybridomas.)
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Figure 4. Fine epitope mapping with peptides indicates that hybridomas recognize a similar
minimal epitope within Tul4
The hybridomas were incubated with C57BL/6 splenocytes, Tul4 peptides, and controls. After
overnight incubation, a beta-galactosidase assay was done to identify activated cells.
Representative data for reactivity patterns are shown (All treatments done 3 times or more).
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Figure 5. Recognition of highly virulent SchuS4 extracts by LVS hybridomas
A small panel of hybridomas generated by infection with LVS or immunization with
recombinant Tul4 from LVS were screened against LVS and SchuS4 extracts. After overnight
incubation, hybridoma reactivity was measured by the CPRG assay. Hybridoma reactivity
against SchuS4 extracts is shown as a percent of the response against LVS extracts after
background subtraction. Representative data for reactivity patterns are shown.
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Figure 6. Tul4 86-99 epitope is recognized in the context of natural infection
A) Gating scheme used to identify viable CD4+ interferon γ+ (IFNγ) cells and exclude B cells,
DCs, and monocyte populations. B & C) Ex vivo splenocytes were activated with ethanol killed
F. tularensis extracts (FT Ag), Tul4 86-99 peptide, OVA, or media alone for 24 hours. Brefeldin
A was added for the last 4 hours of activation before labeling with fluorescent antibodies and
FACS analysis. Representative FACS dot plots of CD4+ cells also gated for IFNγ positivity
from either 7d acutely infected mice (B - top panels) or 2 months post-infection. Percentage
of IFNγ+ CD4+ cells are indicated in each dot plot (C - top panels). Summary of ex vivo
activation experiments, the number of CD4+/IFNγ+ cells per spleen was quantified for 7d acute
infection (B - bottom panels, n = 5) and memory recall (C - bottom panels, n = 2).
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